Global Orally Administered Vaccine market size is predicted to grow from US$ 2908 million in 2025 to US$ 4098 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031. Get Access Now!

Global Orally Administered Vaccine Market Growth Status and Outlook 2025-2031

The global Orally Administered Vaccine market size is predicted to grow from US$ 2908 million in 2025 to US$ 4098 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031. Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection. The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness. Infinity Market Research newest research report, the Orally Administered Vaccine Industry Forecast looks at past sales and reviews total world Orally Administered Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Orally Administered Vaccine sales for 2025 through 2031. With Orally Administered Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orally Administered Vaccine industry. This Insight Report provides a comprehensive analysis of the global Orally Administered Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orally Administered Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Orally Administered Vaccine market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orally Administered Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orally Administered Vaccine. This report presents a comprehensive overview, market shares, and growth opportunities of Orally Administered Vaccine market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Rotavirus Vaccine &nbsp;&nbsp;&nbsp; Cholera Vaccine &nbsp;&nbsp;&nbsp; Oral Polio Vaccine &nbsp;&nbsp;&nbsp; Other Segmentation by Application: &nbsp;&nbsp;&nbsp; Public &nbsp;&nbsp;&nbsp; Private This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; GSK &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Lanzhou Institute &nbsp;&nbsp;&nbsp; Serum Institute &nbsp;&nbsp;&nbsp; Valneva &nbsp;&nbsp;&nbsp; Shanghai United Cell &nbsp;&nbsp;&nbsp; Bibcol &nbsp;&nbsp;&nbsp; PaxVax &nbsp;&nbsp;&nbsp; Vabiotech &nbsp;&nbsp;&nbsp; Tiantan Biological &nbsp;&nbsp;&nbsp; EuBiologics &nbsp;&nbsp;&nbsp; Panacea Biotec Ltd &nbsp;&nbsp;&nbsp; Bio-Med &nbsp;&nbsp;&nbsp; Halfkin Bio-Pharmaceuticals Key Questions Addressed in this Report What is the 10-year outlook for the global Orally Administered Vaccine market? What factors are driving Orally Administered Vaccine market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Orally Administered Vaccine market opportunities vary by end market size? How does Orally Administered Vaccine break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Orally Administered Vaccine Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Orally Administered Vaccine by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Orally Administered Vaccine by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Orally Administered Vaccine Segment by Type &nbsp;2.2.1 Rotavirus Vaccine &nbsp;2.2.2 Cholera Vaccine &nbsp;2.2.3 Oral Polio Vaccine &nbsp;2.2.4 Other &nbsp;2.3 Orally Administered Vaccine Sales by Type &nbsp;2.3.1 Global Orally Administered Vaccine Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Orally Administered Vaccine Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Orally Administered Vaccine Sale Price by Type (2020-2025) &nbsp;2.4 Orally Administered Vaccine Segment by Application &nbsp;2.4.1 Public &nbsp;2.4.2 Private &nbsp;2.5 Orally Administered Vaccine Sales by Application &nbsp;2.5.1 Global Orally Administered Vaccine Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Orally Administered Vaccine Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Orally Administered Vaccine Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Orally Administered Vaccine Breakdown Data by Company &nbsp;3.1.1 Global Orally Administered Vaccine Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Orally Administered Vaccine Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Orally Administered Vaccine Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Orally Administered Vaccine Revenue by Company (2020-2025) &nbsp;3.2.2 Global Orally Administered Vaccine Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Orally Administered Vaccine Sale Price by Company &nbsp;3.4 Key Manufacturers Orally Administered Vaccine Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Orally Administered Vaccine Product Location Distribution &nbsp;3.4.2 Players Orally Administered Vaccine Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Orally Administered Vaccine by Geographic Region &nbsp;4.1 World Historic Orally Administered Vaccine Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Orally Administered Vaccine Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Orally Administered Vaccine Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Orally Administered Vaccine Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Orally Administered Vaccine Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Orally Administered Vaccine Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Orally Administered Vaccine Sales Growth &nbsp;4.4 APAC Orally Administered Vaccine Sales Growth &nbsp;4.5 Europe Orally Administered Vaccine Sales Growth &nbsp;4.6 Middle East & Africa Orally Administered Vaccine Sales Growth 5 Americas &nbsp;5.1 Americas Orally Administered Vaccine Sales by Country &nbsp;5.1.1 Americas Orally Administered Vaccine Sales by Country (2020-2025) &nbsp;5.1.2 Americas Orally Administered Vaccine Revenue by Country (2020-2025) &nbsp;5.2 Americas Orally Administered Vaccine Sales by Type (2020-2025) &nbsp;5.3 Americas Orally Administered Vaccine Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Orally Administered Vaccine Sales by Region &nbsp;6.1.1 APAC Orally Administered Vaccine Sales by Region (2020-2025) &nbsp;6.1.2 APAC Orally Administered Vaccine Revenue by Region (2020-2025) &nbsp;6.2 APAC Orally Administered Vaccine Sales by Type (2020-2025) &nbsp;6.3 APAC Orally Administered Vaccine Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Orally Administered Vaccine by Country &nbsp;7.1.1 Europe Orally Administered Vaccine Sales by Country (2020-2025) &nbsp;7.1.2 Europe Orally Administered Vaccine Revenue by Country (2020-2025) &nbsp;7.2 Europe Orally Administered Vaccine Sales by Type (2020-2025) &nbsp;7.3 Europe Orally Administered Vaccine Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Orally Administered Vaccine by Country &nbsp;8.1.1 Middle East & Africa Orally Administered Vaccine Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Orally Administered Vaccine Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Orally Administered Vaccine Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Orally Administered Vaccine Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Orally Administered Vaccine &nbsp;10.3 Manufacturing Process Analysis of Orally Administered Vaccine &nbsp;10.4 Industry Chain Structure of Orally Administered Vaccine 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Orally Administered Vaccine Distributors &nbsp;11.3 Orally Administered Vaccine Customer 12 World Forecast Review for Orally Administered Vaccine by Geographic Region &nbsp;12.1 Global Orally Administered Vaccine Market Size Forecast by Region &nbsp;12.1.1 Global Orally Administered Vaccine Forecast by Region (2026-2031) &nbsp;12.1.2 Global Orally Administered Vaccine Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Orally Administered Vaccine Forecast by Type (2026-2031) &nbsp;12.7 Global Orally Administered Vaccine Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Merck &nbsp;13.1.1 Merck Company Information &nbsp;13.1.2 Merck Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.1.3 Merck Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Merck Main Business Overview &nbsp;13.1.5 Merck Latest Developments &nbsp;13.2 GSK &nbsp;13.2.1 GSK Company Information &nbsp;13.2.2 GSK Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.2.3 GSK Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 GSK Main Business Overview &nbsp;13.2.5 GSK Latest Developments &nbsp;13.3 Sanofi &nbsp;13.3.1 Sanofi Company Information &nbsp;13.3.2 Sanofi Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.3.3 Sanofi Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Sanofi Main Business Overview &nbsp;13.3.5 Sanofi Latest Developments &nbsp;13.4 Lanzhou Institute &nbsp;13.4.1 Lanzhou Institute Company Information &nbsp;13.4.2 Lanzhou Institute Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.4.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Lanzhou Institute Main Business Overview &nbsp;13.4.5 Lanzhou Institute Latest Developments &nbsp;13.5 Serum Institute &nbsp;13.5.1 Serum Institute Company Information &nbsp;13.5.2 Serum Institute Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.5.3 Serum Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Serum Institute Main Business Overview &nbsp;13.5.5 Serum Institute Latest Developments &nbsp;13.6 Valneva &nbsp;13.6.1 Valneva Company Information &nbsp;13.6.2 Valneva Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.6.3 Valneva Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Valneva Main Business Overview &nbsp;13.6.5 Valneva Latest Developments &nbsp;13.7 Shanghai United Cell &nbsp;13.7.1 Shanghai United Cell Company Information &nbsp;13.7.2 Shanghai United Cell Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.7.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Shanghai United Cell Main Business Overview &nbsp;13.7.5 Shanghai United Cell Latest Developments &nbsp;13.8 Bibcol &nbsp;13.8.1 Bibcol Company Information &nbsp;13.8.2 Bibcol Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.8.3 Bibcol Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Bibcol Main Business Overview &nbsp;13.8.5 Bibcol Latest Developments &nbsp;13.9 PaxVax &nbsp;13.9.1 PaxVax Company Information &nbsp;13.9.2 PaxVax Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.9.3 PaxVax Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 PaxVax Main Business Overview &nbsp;13.9.5 PaxVax Latest Developments &nbsp;13.10 Vabiotech &nbsp;13.10.1 Vabiotech Company Information &nbsp;13.10.2 Vabiotech Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.10.3 Vabiotech Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Vabiotech Main Business Overview &nbsp;13.10.5 Vabiotech Latest Developments &nbsp;13.11 Tiantan Biological &nbsp;13.11.1 Tiantan Biological Company Information &nbsp;13.11.2 Tiantan Biological Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.11.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Tiantan Biological Main Business Overview &nbsp;13.11.5 Tiantan Biological Latest Developments &nbsp;13.12 EuBiologics &nbsp;13.12.1 EuBiologics Company Information &nbsp;13.12.2 EuBiologics Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.12.3 EuBiologics Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 EuBiologics Main Business Overview &nbsp;13.12.5 EuBiologics Latest Developments &nbsp;13.13 Panacea Biotec Ltd &nbsp;13.13.1 Panacea Biotec Ltd Company Information &nbsp;13.13.2 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.13.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Panacea Biotec Ltd Main Business Overview &nbsp;13.13.5 Panacea Biotec Ltd Latest Developments &nbsp;13.14 Bio-Med &nbsp;13.14.1 Bio-Med Company Information &nbsp;13.14.2 Bio-Med Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Bio-Med Main Business Overview &nbsp;13.14.5 Bio-Med Latest Developments &nbsp;13.15 Halfkin Bio-Pharmaceuticals &nbsp;13.15.1 Halfkin Bio-Pharmaceuticals Company Information &nbsp;13.15.2 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolios and Specifications &nbsp;13.15.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview &nbsp;13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments 14 Research Findings and Conclusion

Report	Global Orally Administered Vaccine Market Growth 2025-2031
Selected License	Multi ID: LPI35845

Buyer Information

Order Summary